Finance News – Ozempic
What is your interest today?
- ABC News Business
- BBC Business
- Business Insider Markets
- CBC Business
- City A.M.
- CNBC Business
- CoinDesk
- Cointelegraph
- Crypto News
- CryptoSlate
- Decrypt
- Economic Times Markets
- Euronews Business
- Financial Post Top Stories
- Financial Times
- Finextra Crypto
- Finextra Market
- Finextra Wealth
- Globe and Mail Investing
- Investing.com Global Markets
- Investing.com Global Mkts
- Investopedia
- Kiplinger
- MarketWatch MarketPulse
- MarketWatch Top Stories
- Quartz
- Sky News Money
- Sydney Morning Herald Biz
- Sydney Morning Herald Business
- TechCrunch Fintech
- The Block
- The Guardian – Business
- WSJ Markets News
The weight loss drug boom has barely begun. How big can it get?
The rising popularity of GLP-1 medications, including Ozempic, positions them to generate substantial revenue, potentially surpassing established blockbuster drugs like statins in...
Read Full Article →A $250 mistake seems set to cost Ozempic maker Novo Nordisk billions
Novo Nordisk is expected to face substantial financial losses as Canada prepares to introduce generic alternatives of its weight loss medication due to the company’s failure to mai...
Read Full Article →Healthy Returns: Ozempic, Wegovy linked to rare cases of serious eye condition
Novo Nordisk’s medications associated with uncommon but severe eye issues may impact the company’s valuation, as emerging health technology firms continue to gain significant inves...
Read Full Article →Activist hedge fund builds stake in Ozempic-maker Novo Nordisk
An investment firm has increased its holdings in the Danish pharmaceutical company known for its diabetes treatment, signaling confidence amid leadership changes and recent decline...
Read Full Article →How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race
Despite its initial leadership in the growing weight loss medication sector, Novo Nordisk has recently experienced a decline in market share compared to Eli Lilly, affecting its fi...
Read Full Article →Ozempic-maker Novo Nordisk ousts CEO after shares plummet
Novo Nordisk's decision to replace its CEO follows a significant decline in the company’s stock value, underscoring the financial impact of recent market challenges on the pharmace...
Read Full Article →Novo Nordisk's CEO is out after the Ozempic maker's stock dropped 50% in a year
Novo Nordisk announced that its CEO, Lars Fruergaard Jørgensen, will resign following a significant decline in the company’s market value linked to challenges faced by its key diab...
Read Full Article →Ozempic maker Novo Nordisk boots CEO over stock-price fall
The departure of Novo Nordisk's CEO follows a decline in the company's market value, highlighting investor concerns about future financial performance in the competitive pharmaceut...
Read Full Article →Weight Watchers goes bankrupt even as it tries to ride the Ozempic boom
WeightWatchers has filed for bankruptcy due to over $1 billion in debt, aiming to restructure its finances while shifting focus toward weight loss medications such as GLP-1 treatme...
Read Full Article →